Developer docs
API playgroundTry for free, no card

Search company profiles

Amprion

Full company profile

uuid02lzyby

Namestring
Amprion
Legal namestring
Amprion, Inc.
Websiteurl
ampriondx.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Amprion, Inc. is a privately held diagnostics company founded in 2014 and headquartered in San Diego, California, that develops and commercializes seed amplification assay (SAA) technology for detecting misfolded proteins associated with neurodegenerative diseases. The company's flagship product, the SAAmplify-αSYN test (formerly SYNTap), is the first clinically available and validated cerebrospinal fluid (CSF) assay for detecting pathological α-synuclein with autopsy-confirmed accuracy, reporting 96% sensitivity and 92% specificity for alpha-synuclein pathology and over 98% correlation with diffuse Lewy body disease in autopsy cohorts. The test is performed at Amprion's CAP-accredited and CLIA-certified clinical laboratory (the world's first such facility for SAA testing) and is offered as a Laboratory Developed Test (LDT) commercially available for clinical and research use.

Amprion operates a hybrid business model with two principal revenue streams: (1) clinical laboratory testing services billed through physician orders (neurologists, geriatricians, and psychiatrists prescribe the test, which requires a lumbar puncture and CSF sample shipped to the San Diego lab), with reimbursement pursued across Medicare, Medicaid, and private insurers; and (2) biopharma partnership services including patient stratification, endpoint selection, target engagement studies, preclinical/assay development, and project management for drug developers. The platform is supported by an extensive intellectual property portfolio spanning the US, Europe, Asia, and other jurisdictions, covering detection methodology, substrates, and differential diagnosis applications (e.g., discriminating Parkinson's from multiple system atrophy).

The company is founder-led by CEO Dr. Russell Lebovitz and CSO Dr. Claudio Soto (the inventor of the underlying SAA technology, awarded the 2024 Robert A. Pritzker Prize). Amprion serves three primary customer segments: patients and care partners seeking biological diagnostic clarity, clinicians ordering the test for diagnostic and treatment-decision support, and biopharma enterprises using the assay for clinical trial biomarker services. Strategic distribution is anchored in physician ordering via Amprion's website, complemented by annual participation in major neurodegenerative disease conferences (AAN, AD/PD, AAIC, MDS, ANPA, CTAD) and embedded research partnerships with MJFF, ADDF, Parkinson's Foundation, ADNI, and NIA. The company also markets itself through its NeuroSAAvvy blog and peer-reviewed scientific publications.

Short descriptiontext

Amprion is a San Diego-based clinical diagnostics company that develops and commercializes the SAAmplify-αSYN seed amplification assay, the first clinically validated test for detecting misfolded α-synuclein in cerebrospinal fluid to diagnose Parkinson's, Lewy body dementia, and related neurodegenerative diseases, serving clinicians, patients, and biopharma partners.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
seed amplification assays, neurodegenerative diagnostics, alpha-synuclein testing, biomarker laboratory services, clinical diagnostic testing
Industry5 codes
PRIMARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing
SECONDARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAEAG
Bioanalytical & PK/PD Sample Analysis (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAMAD
Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code4 codes
  • Medical and Diagnostic Laboratories6215
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code4 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
  • Services-Testing Laboratories8734
Product category
Clinical Diagnostic Laboratory Services (Neurodegenerative Disease Diagnostics)
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Clinical Laboratory Testing Services
TypeSubscription Recurring
Description

Amprion generates revenue through providing clinical diagnostic testing services via its CAP/CLIA-certified laboratory. The SAAmplify-αSYN test is offered as a Laboratory Developed Test (LDT) commercially available for clinical use. Revenue comes from test fees billed to insurance (Medicare, Medicaid, private insurers) or self-pay patients.

ampriondx.com
2Biopharma Partnership Services
TypeProfessional Services
Description

Amprion provides biomarker detection services to pharmaceutical companies for clinical trial support, including patient stratification, endpoint selection, and monitoring in drug development programs. Services include project management, sample logistics, data management, and assay services.

ampriondx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Pricing details1 tier
1Insurance-covered testing
ModelOtherBilling cadencePay-as-you-go
Notes

Many insurance plans cover the test when ordered by a doctor. Amprion offers courtesy billing on behalf of patients and provides self-pay basis options.

ampriondx.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1SAAmplify-αSYN
Description

Seed amplification assay test for detecting misfolded α-synuclein proteins in cerebrospinal fluid, used for diagnosis of Parkinson's disease, Lewy body dementia, and Alzheimer's with Lewy body co-pathology. Formerly known as SYNTap.

ampriondx.com
+1 more record
Core offering1 text field

Amprion commercializes the SAAmplify-αSYN test, a cerebrospinal fluid (CSF)-based Seed Amplification Assay that detects misfolded α-synuclein proteins with 96% sensitivity and 92% specificity, providing autopsy-confirmed biological confirmation of synucleinopathies including Parkinson's disease, Dementia with Lewy bodies, Multiple System Atrophy, and Alzheimer's with Lewy body co-pathology. The company also offers Research Use Only (RUO) qualitative and semi-quantitative SAA assay variants for biopharma drug development, and a suite of R&D laboratory services encompassing target engagement studies, preclinical proof-of-concept studies, custom assay development, and biopharma project management and data services.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Amprion offers a diagnostic testing platform centered on its proprietary Seed Amplification Assay (SAA) technology. The core product is the SAAmplify-αSYN test (formerly SYNTap), the first and only commercially available clinically validated test that detects misfolded α-synuclein in cerebrospinal fluid with autopsy-confirmed accuracy. The platform also includes Research Use Only (RUO) assays for biopharma drug development, semi-quantitative variants for enhanced research sensitivity, and comprehensive R&D laboratory services including target engagement studies, preclinical studies, and custom assay development. Services extend to biopharma partners through project management, sample logistics coordination, results reporting, and data management solutions. The company operates the world's first and only CAP/CLIA-certified laboratory offering SAA technology as a Laboratory Developed Test (LDT) for clinical and research use.

Product and service6 records
1SAAmplify-αSYN Test
CategoryClinical Diagnostic Test (LDT)
Description

A cerebrospinal fluid (CSF)-based Seed Amplification Assay (SAA) sold as a Laboratory Developed Test (LDT) that detects misfolded α-synuclein proteins with 96% sensitivity and 92% specificity, providing autopsy-confirmed accuracy for diagnosing Parkinson's disease, Dementia with Lewy bodies, Multiple System Atrophy, and Alzheimer's with Lewy body co-pathology. Ordered by physicians via lumbar puncture; samples are shipped to Amprion's CAP/CLIA-certified San Diego laboratory for analysis.

2SAAmplify-αSYN RUO Qualitative synSAA
CategoryResearch Use Only Assay
Description

Research Use Only qualitative seed amplification assay enhanced for multiple system atrophy (MSA) detection, sold to biopharma and academic research programs as part of Amprion's expanded laboratory services.

3SAAmplify-αSYN RUO Semi-Quantitative synSAA for PD/DLB
CategoryResearch Use Only Assay
Description

Research Use Only semi-quantitative seed amplification assay for Parkinson's disease and Dementia with Lewy bodies, sold to research programs to enable more granular measurement of seeding activity for research applications.

4SAAmplify-αSYN RUO Semi-Quantitative synSAA for MSA
CategoryResearch Use Only Assay
Description

Research Use Only semi-quantitative seed amplification assay optimized for multiple system atrophy (MSA), sold to research programs to support differential diagnosis research between PD/DLB and MSA synucleinopathies.

5R&D Laboratory Services
CategoryBiopharma R&D Services
Description

Research and development services sold to biopharma partners, including target engagement studies, mechanism of action analysis, drug interference screening in SAA, kinetic parameter analysis, proof-of-concept and preclinical studies (animal models, iPSC cellular models, serial dilution studies, seeding activity impact), and custom assay development (peripheral matrices such as blood and skin, tissue extraction protocol optimization, seed enrichment, and additional misfolded protein assays).

6Biopharma Project Management & Data Services
CategoryBiopharma Project & Data Services
Description

Comprehensive enterprise services for biopharma clients including project acquisition, implementation management, timeline analysis, contracting, clinical lab audits, data transfer agreements, and data upload services to designated CRO or data vendors.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-07-09
Description

Partnership for multimodal assessment in neurodegenerative disease combining Amprion's SAAmplify-αSYN biomarker testing with Modality.AI's AI-powered assessment technologies for more comprehensive patient evaluation.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-07-03
Description

$5 million partnership between ADDF's Diagnostics Accelerator (DxA) and MJFF to accelerate development of minimally invasive biomarkers for measuring pathologies in Parkinson's and Alzheimer's diseases. Focuses on detecting alpha-synuclein co-pathology. Builds on prior investments including the cerebrospinal fluid assay by University of Texas scientists that led to Amprion's spinout. Amprion partnered with MJFF's Parkinson's Precision Medicine Initiative (PPMI).

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-01
Description

Amprion expanded global footprint through Australian partnership and expanded research collaborations supporting international biomarker research initiatives.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

In 2023, MJFF announced a breakthrough facilitated by Amprion's SAAmplify-αSYN test, stating it 'heralds the revolutionary ability for research to define Parkinson's disease biologically, offering a critical tool for clinical trial design and assessment of treatment effects, and for early detection of disease pathology.'

5Alzheimer's Disease Neuroimaging Initiative (ADNI)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research partnership contributing data and samples to ADNI, a major public-private partnership focused on Alzheimer's disease research biomarker validation.

ampriondx.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration with the Parkinson's Foundation to advance understanding of neurodegenerative disease biomarkers and improve patient outcomes.

7National Institute on Aging (NIA)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research partnership supported by NIA, part of NIH, for advancing neurodegenerative disease research and biomarker development.

ampriondx.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Quanterix provides ultra-sensitive single-molecule array biomarker detection platforms used in neurodegenerative disease research and pharma biomarker services, making it a direct peer in the high-sensitivity biomarker measurement and biopharma services space.

TypeDirect peer
Description

C2N Diagnostics commercializes the PrecivityAD blood-based biomarker test for Alzheimer's pathology, making it a direct peer to Amprion in biological confirmation of neurodegenerative disease biology using proprietary assay platforms sold to clinicians and biopharma.

TypeBroad incumbent
Description

Roche operates the world's largest in-vitro diagnostics business with Elecsys CSF assays for Alzheimer's and an active neurodegenerative disease pipeline. It is a broad incumbent competing with Amprion across clinical diagnostic menus and pharma trial biomarker services.

TypeBroad incumbent
Description

Biogen has strategic interests in neurodegenerative diagnostics tied to its Alzheimer's therapeutic portfolio (aducanumab, lecanemab) and has historically invested in biomarker collaborations. It is a broad incumbent with overlapping CNS biomarker strategy and partnerships.

TypeBroad incumbent
Description

Fujirebio is a leading Japanese diagnostics company with an established CSF biomarker portfolio (amyloid-beta, tau) and global pharma services, making it a broad incumbent in neurodegenerative disease testing adjacent to Amprion's CSF SAA platform.

6ADx NeuroSciences
TypeDirect peer
Description

ADx NeuroSciences develops immunoassays for Alzheimer's, Parkinson's, and other neurodegenerative biomarkers, including alpha-synuclein assays. It is a direct peer given overlapping target proteins, assay technologies, and biopharma/biomarker services business model.

TypeEmerging player
Description

Araclon Biotech develops blood-based biomarker tests (ABtest) for Alzheimer's disease amyloid pathology and is an emerging player in neurodegenerative diagnostics. It is comparable to Amprion in focus on biological confirmation of CNS proteinopathies, though concentrated on amyloid rather than alpha-synuclein.

TypeEmerging player
Description

Prothena develops alpha-synuclein-targeted therapies and biomarker programs for synucleinopathies and is both a potential customer (biopharma services) and adjacent player in defining biological diagnostic standards for Parkinson's — relevant as a peer given shared focus on alpha-synuclein biology.

9Euroimmun (Revvity / PerkinElmer)
TypeBroad incumbent
Description

Euroimmun, now part of Revvity, provides a broad menu of neurodegenerative autoantibody and biomarker assays including alpha-synuclein and tau ELISAs. It is a broad incumbent offering overlapping CNS diagnostic capabilities with global commercial reach.

TypeBroad incumbent
Description

Eli Lilly has invested heavily in tau diagnostic development (via Avid Radiopharmaceuticals) and amyloid biomarkers to support its Alzheimer's therapeutics franchise. It competes with Amprion as a deep-pocketed incumbent integrating biomarkers with disease-modifying therapy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Amprion

Clinical Diagnostic Laboratory Services (Neurodegenerative Disease Diagnostics)ampriondx.com

Amprion is a San Diego-based clinical diagnostics company that develops and commercializes the SAAmplify-αSYN seed amplification assay, the first clinically validated test for detecting misfolded α-synuclein in cerebrospinal fluid to diagnose Parkinson's, Lewy body dementia, and related neurodegenerative diseases, serving clinicians, patients, and biopharma partners.

What Amprion does

Amprion, Inc. is a privately held diagnostics company founded in 2014 and headquartered in San Diego, California, that develops and commercializes seed amplification assay (SAA) technology for detecting misfolded proteins associated with neurodegenerative diseases. The company's flagship product, the SAAmplify-αSYN test (formerly SYNTap), is the first clinically available and validated cerebrospinal fluid (CSF) assay for detecting pathological α-synuclein with autopsy-confirmed accuracy, reporting 96% sensitivity and 92% specificity for alpha-synuclein pathology and over 98% correlation with diffuse Lewy body disease in autopsy cohorts. The test is performed at Amprion's CAP-accredited and CLIA-certified clinical laboratory (the world's first such facility for SAA testing) and is offered as a Laboratory Developed Test (LDT) commercially available for clinical and research use.

Amprion operates a hybrid business model with two principal revenue streams: (1) clinical laboratory testing services billed through physician orders (neurologists, geriatricians, and psychiatrists prescribe the test, which requires a lumbar puncture and CSF sample shipped to the San Diego lab), with reimbursement pursued across Medicare, Medicaid, and private insurers; and (2) biopharma partnership services including patient stratification, endpoint selection, target engagement studies, preclinical/assay development, and project management for drug developers. The platform is supported by an extensive intellectual property portfolio spanning the US, Europe, Asia, and other jurisdictions, covering detection methodology, substrates, and differential diagnosis applications (e.g., discriminating Parkinson's from multiple system atrophy).

The company is founder-led by CEO Dr. Russell Lebovitz and CSO Dr. Claudio Soto (the inventor of the underlying SAA technology, awarded the 2024 Robert A. Pritzker Prize). Amprion serves three primary customer segments: patients and care partners seeking biological diagnostic clarity, clinicians ordering the test for diagnostic and treatment-decision support, and biopharma enterprises using the assay for clinical trial biomarker services. Strategic distribution is anchored in physician ordering via Amprion's website, complemented by annual participation in major neurodegenerative disease conferences (AAN, AD/PD, AAIC, MDS, ANPA, CTAD) and embedded research partnerships with MJFF, ADDF, Parkinson's Foundation, ADNI, and NIA. The company also markets itself through its NeuroSAAvvy blog and peer-reviewed scientific publications.

Amprion firmographics

Firmographics
Name
Amprion
Legal name
Amprion, Inc.
Website
https://ampriondx.com
Company type
Private
Founded year
2014
Operating status
Operating
Short description
Amprion is a San Diego-based clinical diagnostics company that develops and commercializes the SAAmplify-αSYN seed amplification assay, the first clinically validated test for detecting misfolded α-synuclein in cerebrospinal fluid to diagnose Parkinson's, Lewy body dementia, and related neurodegenerative diseases, serving clinicians, patients, and biopharma partners.
Ownership category
akta.pro rank

Amprion industry classification

Industry
Product category
Clinical Diagnostic Laboratory Services (Neurodegenerative Disease Diagnostics)
NAICS
Medical and Diagnostic Laboratories (6215), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing
SECONDARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAEAG
Bioanalytical & PK/PD Sample Analysis (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAMAD
Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Seed amplification assays
  • Neurodegenerative diagnostics
  • Alpha-synuclein testing
  • Biomarker laboratory services
  • Clinical diagnostic testing

Where Amprion is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Amprion business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. Clinical Laboratory Testing Services: Amprion generates revenue through providing clinical diagnostic testing services via its CAP/CLIA-certified laboratory. The SAAmplify-αSYN test is offered as a Laboratory Developed Test (LDT) commercially available for clinical use. Revenue comes from test fees billed to insurance (Medicare, Medicaid, private insurers) or self-pay patients.
  2. Biopharma Partnership Services: Amprion provides biomarker detection services to pharmaceutical companies for clinical trial support, including patient stratification, endpoint selection, and monitoring in drug development programs. Services include project management, sample logistics, data management, and assay services.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goInsurance-covered testing

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Amprion product offering

Product offering

Core offering

Amprion commercializes the SAAmplify-αSYN test, a cerebrospinal fluid (CSF)-based Seed Amplification Assay that detects misfolded α-synuclein proteins with 96% sensitivity and 92% specificity, providing autopsy-confirmed biological confirmation of synucleinopathies including Parkinson's disease, Dementia with Lewy bodies, Multiple System Atrophy, and Alzheimer's with Lewy body co-pathology. The company also offers Research Use Only (RUO) qualitative and semi-quantitative SAA assay variants for biopharma drug development, and a suite of R&D laboratory services encompassing target engagement studies, preclinical proof-of-concept studies, custom assay development, and biopharma project management and data services.

Product overview

Amprion offers a diagnostic testing platform centered on its proprietary Seed Amplification Assay (SAA) technology. The core product is the SAAmplify-αSYN test (formerly SYNTap), the first and only commercially available clinically validated test that detects misfolded α-synuclein in cerebrospinal fluid with autopsy-confirmed accuracy. The platform also includes Research Use Only (RUO) assays for biopharma drug development, semi-quantitative variants for enhanced research sensitivity, and comprehensive R&D laboratory services including target engagement studies, preclinical studies, and custom assay development. Services extend to biopharma partners through project management, sample logistics coordination, results reporting, and data management solutions. The company operates the world's first and only CAP/CLIA-certified laboratory offering SAA technology as a Laboratory Developed Test (LDT) for clinical and research use.

Differentiator

Problem solved

Functional benefit

Brands

  • SAAmplify-αSYN: Seed amplification assay test for detecting misfolded α-synuclein proteins in cerebrospinal fluid, used for diagnosis of Parkinson's disease, Lewy body dementia, and Alzheimer's with Lewy body co-pathology. Formerly known as SYNTap.
  • NeuroSAAvvy

Products and services

  • SAAmplify-αSYN Test A cerebrospinal fluid (CSF)-based Seed Amplification Assay (SAA) sold as a Laboratory Developed Test (LDT) that detects misfolded α-synuclein proteins with 96% sensitivity and 92% specificity, providing autopsy-confirmed accuracy for diagnosing Parkinson's disease, Dementia with Lewy bodies, Multiple System Atrophy, and Alzheimer's with Lewy body co-pathology. Ordered by physicians via lumbar puncture; samples are shipped to Amprion's CAP/CLIA-certified San Diego laboratory for analysis.
  • SAAmplify-αSYN RUO Qualitative synSAA Research Use Only qualitative seed amplification assay enhanced for multiple system atrophy (MSA) detection, sold to biopharma and academic research programs as part of Amprion's expanded laboratory services.
  • SAAmplify-αSYN RUO Semi-Quantitative synSAA for PD/DLB Research Use Only semi-quantitative seed amplification assay for Parkinson's disease and Dementia with Lewy bodies, sold to research programs to enable more granular measurement of seeding activity for research applications.
  • SAAmplify-αSYN RUO Semi-Quantitative synSAA for MSA Research Use Only semi-quantitative seed amplification assay optimized for multiple system atrophy (MSA), sold to research programs to support differential diagnosis research between PD/DLB and MSA synucleinopathies.
  • R&D Laboratory Services Research and development services sold to biopharma partners, including target engagement studies, mechanism of action analysis, drug interference screening in SAA, kinetic parameter analysis, proof-of-concept and preclinical studies (animal models, iPSC cellular models, serial dilution studies, seeding activity impact), and custom assay development (peripheral matrices such as blood and skin, tissue extraction protocol optimization, seed enrichment, and additional misfolded protein assays).
  • Biopharma Project Management & Data Services Comprehensive enterprise services for biopharma clients including project acquisition, implementation management, timeline analysis, contracting, clinical lab audits, data transfer agreements, and data upload services to designated CRO or data vendors.

Companies that use Amprion

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Amprion technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Amprion partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core, flagship and minor.

  • Modality.AIcoreTechnology or Integration · 9 July 2026Partnership for multimodal assessment in neurodegenerative disease combining Amprion's SAAmplify-αSYN biomarker testing with Modality.AI's AI-powered assessment technologies for more comprehensive patient evaluation.
  • Michael J. Fox Foundation for Parkinson's ResearchflagshipStrategic or Co-development Partner · 3 July 2026$5 million partnership between ADDF's Diagnostics Accelerator (DxA) and MJFF to accelerate development of minimally invasive biomarkers for measuring pathologies in Parkinson's and Alzheimer's diseases. Focuses on detecting alpha-synuclein co-pathology. Builds on prior investments including the cerebrospinal fluid assay by University of Texas scientists that led to Amprion's spinout. Amprion partnered with MJFF's Parkinson's Precision Medicine Initiative (PPMI).
  • Australian Research PartnersminorStrategic or Co-development Partner · 1 April 2026Amprion expanded global footprint through Australian partnership and expanded research collaborations supporting international biomarker research initiatives.
  • Michael J. Fox FoundationflagshipStrategic or Co-development PartnerIn 2023, MJFF announced a breakthrough facilitated by Amprion's SAAmplify-αSYN test, stating it 'heralds the revolutionary ability for research to define Parkinson's disease biologically, offering a critical tool for clinical trial design and assessment of treatment effects, and for early detection of disease pathology.'
  • Alzheimer's Disease Neuroimaging Initiative (ADNI)coreStrategic or Co-development PartnerResearch partnership contributing data and samples to ADNI, a major public-private partnership focused on Alzheimer's disease research biomarker validation.
  • Parkinson's FoundationcoreStrategic or Co-development PartnerResearch collaboration with the Parkinson's Foundation to advance understanding of neurodegenerative disease biomarkers and improve patient outcomes.
  • National Institute on Aging (NIA)coreStrategic or Co-development PartnerResearch partnership supported by NIA, part of NIH, for advancing neurodegenerative disease research and biomarker development.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Amprion competitors and assessment

Company assessment

Direct peers

  • Quanterix: Quanterix provides ultra-sensitive single-molecule array biomarker detection platforms used in neurodegenerative disease research and pharma biomarker services, making it a direct peer in the high-sensitivity biomarker measurement and biopharma services space.
  • C2N Diagnostics: C2N Diagnostics commercializes the PrecivityAD blood-based biomarker test for Alzheimer's pathology, making it a direct peer to Amprion in biological confirmation of neurodegenerative disease biology using proprietary assay platforms sold to clinicians and biopharma.
  • ADx NeuroSciences: ADx NeuroSciences develops immunoassays for Alzheimer's, Parkinson's, and other neurodegenerative biomarkers, including alpha-synuclein assays. It is a direct peer given overlapping target proteins, assay technologies, and biopharma/biomarker services business model.

Broad incumbents

  • Roche Diagnostics: Roche operates the world's largest in-vitro diagnostics business with Elecsys CSF assays for Alzheimer's and an active neurodegenerative disease pipeline. It is a broad incumbent competing with Amprion across clinical diagnostic menus and pharma trial biomarker services.
  • Biogen: Biogen has strategic interests in neurodegenerative diagnostics tied to its Alzheimer's therapeutic portfolio (aducanumab, lecanemab) and has historically invested in biomarker collaborations. It is a broad incumbent with overlapping CNS biomarker strategy and partnerships.
  • Fujirebio: Fujirebio is a leading Japanese diagnostics company with an established CSF biomarker portfolio (amyloid-beta, tau) and global pharma services, making it a broad incumbent in neurodegenerative disease testing adjacent to Amprion's CSF SAA platform.
  • Euroimmun (Revvity / PerkinElmer): Euroimmun, now part of Revvity, provides a broad menu of neurodegenerative autoantibody and biomarker assays including alpha-synuclein and tau ELISAs. It is a broad incumbent offering overlapping CNS diagnostic capabilities with global commercial reach.
  • Eli Lilly: Eli Lilly has invested heavily in tau diagnostic development (via Avid Radiopharmaceuticals) and amyloid biomarkers to support its Alzheimer's therapeutics franchise. It competes with Amprion as a deep-pocketed incumbent integrating biomarkers with disease-modifying therapy.

Emerging players

  • Araclon Biotech: Araclon Biotech develops blood-based biomarker tests (ABtest) for Alzheimer's disease amyloid pathology and is an emerging player in neurodegenerative diagnostics. It is comparable to Amprion in focus on biological confirmation of CNS proteinopathies, though concentrated on amyloid rather than alpha-synuclein.
  • Prothena Biosciences: Prothena develops alpha-synuclein-targeted therapies and biomarker programs for synucleinopathies and is both a potential customer (biopharma services) and adjacent player in defining biological diagnostic standards for Parkinson's — relevant as a peer given shared focus on alpha-synuclein biology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Amprion social profiles

Digital presence

Amprion compliance and trust

Trust signal

Compliance8 records

Amprion financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Amprion leadership team

Management profile

Number of profiles

Profiles14 records

Amprion funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Amprion M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amprion

What does Amprion do?

Amprion commercializes the SAAmplify-αSYN test, a cerebrospinal fluid (CSF)-based Seed Amplification Assay that detects misfolded α-synuclein proteins with 96% sensitivity and 92% specificity, providing autopsy-confirmed biological confirmation of synucleinopathies including Parkinson's disease, Dementia with Lewy bodies, Multiple System Atrophy, and Alzheimer's with Lewy body co-pathology. The company also offers Research Use Only (RUO) qualitative and semi-quantitative SAA assay variants for biopharma drug development, and a suite of R&D laboratory services encompassing target engagement studies, preclinical proof-of-concept studies, custom assay development, and biopharma project management and data services.

Is Amprion a public or private company?

Amprion is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Amprion founded?

Amprion was founded in 2014.

Where is Amprion based?

Amprion is headquartered in San Diego, United States, in the North America region.

How does Amprion make money?

Two revenue lines are on record. Clinical Laboratory Testing Services are the primary driver. The others are biopharma Partnership Services.

Who are Amprion's main competitors?

Direct peers on record are Quanterix, C2N Diagnostics and ADx NeuroSciences. Broad incumbents are Roche Diagnostics, Biogen, Fujirebio, Euroimmun (Revvity / PerkinElmer) and Eli Lilly. Emerging players are Araclon Biotech and Prothena Biosciences.

Does Amprion have an API?

No public API is recorded for Amprion.

What industry is Amprion in?

Amprion's product category is Clinical Diagnostic Laboratory Services (Neurodegenerative Disease Diagnostics). Its primary akta.pro industry code is HLAAALAN, Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays, with a secondary code of HLAGADAG, Proteomics & Biomarker Analytical Testing. Its NAICS code is 6215 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyAmprion, Prema Cognition build accessible pathway for early neurodegenerative disease detectionAmprion and Prema Cognition announced a collaboration to combine PREMAZ, a digital memory test, with Amprion's SAAmplify-αSYN seed amplification assay. The partnership aims to create a patient assessment pathway linking remote or clinic-based cognitive screening to biomarker confirmation for early neurodegenerative disease detection.Longevity.TechnologyAmprion partners with MLM Medical Labs to expand α-synuclein testingAmprion has entered a strategic licensing collaboration with MLM Medical Labs to expand α-synuclein seed amplification assay testing across Europe. Under the agreement, Amprion licenses its SAAmplify-αSYN methodology to MLM, enabling the latter to perform in-house IVD testing for biopharma-sponsored clinical trials at its German laboratory.FinancialContent Business PageAmprion Partners with MLM Medical Labs to Expand Alpha-Synuclein SAA Testing in EuropeAmprion has entered a strategic licensing collaboration with MLM Medical Labs to expand the availability of its SAAmplify-αSYN seed amplification assay for neurodegenerative disease testing in Europe. Under this agreement, MLM Medical Labs will validate and perform the α-synuclein testing as an in-house IVD at its German laboratory to support biopharma-sponsored clinical trials. This partnership aims to accelerate research and therapeutic development by providing broader access to pathology-based biomarker testing across European trial sites.Business Wire BlogAmprion Partners with MLM Medical Labs to Expand Alpha-Synuclein SAA Testing in EuropeAmprion announced a strategic licensing collaboration with MLM Medical Labs to expand access to its SAAmplify-αSYN seed amplification assay for neurodegenerative disease research in Europe. Under the agreement, MLM Medical Labs will validate and perform the testing as an in-house IVD at its German laboratory for biopharma-sponsored clinical trials. This partnership aims to accelerate drug development by providing European trial sites with pathology-based biomarker testing capabilities.AijournAmprion To Expand Diagnostic Testing For Neurodegenerative Disorders With Investment From Decathlon Capital PartnersAmprion, Inc., a San Diego-based diagnostic company specializing in neurodegenerative disorder testing, has secured a multi-million-dollar growth-funding investment from Decathlon Capital Partners. The capital will be used to expand Amprion's diagnostic testing capacity for conditions including Parkinson's disease, Lewy body dementia, and Alzheimer's disease. The financing package is structured as non-dilutive, allowing Amprion to maintain operational flexibility and management control while scaling its seed-amplification testing platform.PR NewswireAmprion To Expand Diagnostic Testing For Neurodegenerative Disorders With Investment From Decathlon Capital PartnersAmprion, Inc., a San Diego-based company specializing in seed-amplification testing for neurodegenerative disorders, has secured a multi-million dollar growth-funding investment from Decathlon Capital Partners. The investment will be used to expand diagnostic testing capacity for diseases including Parkinson's disease, Lewy body dementia, and Alzheimer's disease. The financing arrangement is structured as non-dilutive, providing operational flexibility while preserving existing shareholder value and management control.BitlyAmprion To Expand Diagnostic Testing For Neurogenerative Disorders With Investment From Decathlon Capital PartnersAmprion, Inc., a San Diego-based company specializing in seed-amplification diagnostic testing for neurodegenerative disorders, has secured a multi-million-dollar growth-funding investment from Decathlon Capital Partners. The funding will be used to expand testing capacity for conditions including Parkinson's disease, Lewy body dementia, and Alzheimer's disease. The financing package is structured as non-dilutive, allowing Amprion to maintain management control while supporting its global expansion strategy.ParkinsonsnewstodayAmprion working to expand access to alpha-synuclein protein testAmprion has partnered with Macquarie University in Australia to establish the country's first alpha-synuclein seed amplification testing site, marking a key step in its international expansion. This collaboration aims to improve early diagnosis of Parkinson’s and related neurodegenerative diseases through the SAAmplify-alphaSYN test. The company is simultaneously strengthening its global intellectual property portfolio and expanding partnerships in Europe, South Korea, and China.Business Wire BlogAmprion Announces Strategic Growth Initiatives, Expanding Access to Breakthrough SAAmplify TestAmprion announced strategic growth initiatives including a website refresh and expanded availability of its SAAmplify-ɑSYN test through Mayo Clinic's network, alongside preparations for international expansion. The company plans to showcase these developments at the Alzheimer’s Association International Conference in Toronto and expects to announce country-specific launch strategies for European and global markets in Q4 2025. These moves aim to broaden access to the diagnostic tool for synucleinopathies amid growing demand.MayoclinicMayo Clinic Laboratories and Amprion announce collaboration to advance neurodegenerative disease diagnosticsMayo Clinic Laboratories and Amprion announced a collaboration to expand access to Amprion's SAAmplify–αSYN (CSF) test across the United States. This partnership combines the expertise of both organizations to enhance patient care and improve diagnostic accuracy for neurodegenerative diseases. The test is now available for clients of Mayo Clinic Laboratories.